Company: RPTX
Filing Date: 2025-11-14
Form Type: DEFA14A
Source: 0001193125-25-283320
Chunk: 7

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-14
Form: DEFA14A
Chunk 7
---
pline safety, tolerability 
 and early efficacy data from the POLAR trial in monotherapy and in combination with Olaparib.                    |

| • |     | RP-1664: First-in-class, oral selective PLK4 Inhibitor |

| • |     | The Company recently presented positive initial topline safety, tolerability and early efficacy data from its                                                                                                                                    
 Phase 1 LIONS clinical trial, evaluating RP-1664 as a monotherapy in adult and adolescent patients with TRIM37-high solid tumors at the 37th AACR-NCI-EORTC International Conference on Molecular                                                
 Targets and Cancer Therapeutics. The encouraging tolerability and efficacy data support the use of RP-1664 as a monotherapy in molecularly selected tumor specific cohorts and support further investigation of PLK4 inhibition as a therapeutic 
 modality, especially among less pretreated patients.                                                                                                                                                                                             |

Third Quarter 2025 Financial Results

| • |     | Cash, cash equivalents and marketable securities: Cash, cash equivalents and marketable securities as of 
 September 30, 2025 were $112.6 million, as compared to $109.5 million as of June 30, 2025.               |

| • |     | Revenue from collaboration agreements: Revenue from collaboration agreements were $11.6 million and                                                                          
 $11.9 million for the three and nine months ended September 30, 2025, respectively, as compared to nil and $53.5 million for three and nine months ended September 30, 2024. |

| • |     | Research and development expense, net of tax credits (Net R&D): Net R&D expenses were $7.5 million                                                                                             
 and $42.1 million for the three and nine months ended September 30, 2025, respectively, as compared to $28.4 million and $91.5 million for the three and nine months ended September 30, 2024. |

| • |     | General and administrative (G&A) expenses: G&A expenses were $4.5 million and $18.2 million for                                                                      
 the three and nine months ended September 30, 2025, respectively, compared to $6.4 million and $23.4 million for the three and nine months ended September 30, 2024. |

| • |     | Net income (loss): Net income of $3.3 million, or $0.08 diluted per share, and net loss of